EMA sends more questions to GLP-1 makers over possible risk of suicide, self-harm
The European Medicines Agency’s safety committee on Friday raised more questions for the makers of GLP-1 weight loss drugs after reported cases of thoughts of suicide and self-harm and a safety signal issued in November.
The committee said it reviewed clinical trials, post-marketing surveillance and published literature on the issue and sent additional questions to the major makers of the drug, adding that “while at this point no conclusion can be drawn on a causal association, there are several issues that still need to be clarified.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
